Abstract
Lung cancer continues to be the leading cause of cancer-related deaths in the western civilization and developing countries. Non-small cell lung cancer (NSCLC) accounts for > 85% of all cases of lung cancer. Since most patients with NSCLC have advanced disease at diagnosis, to date chemotherapy with third-generation platinum-based doublets represents the standard of care. However, a plateau has been reached with the use of cytotoxic chemotherapy in advanced NSCLC. Advances in the knowledge of tumour biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. In particular, the epidermal growth factor receptor (EGFR), a member of the ErbB family and commonly overexpressed in NSCLC, is one of the most studied targets. Overexpression of EGFR has been associated with a poorer prognosis in patients with cancer, therefore its inhibition may lead to the suppression of tumor proliferation improving clinical outcome. Strategies to block EGFR include development of monoclonal antibodies to EGFR, tyrosine kinase inhibitors, ligand-linked toxins, and antisense approaches. This article will focus on cetuximab and other monoclonal antibodies and their applications in the treatment of advanced NSCLC.
Keywords: EGFR, monoclonal antibodies, NSCLC, cetuximab, panitumumab, matuzumab
Reviews on Recent Clinical Trials
Title: The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer
Volume: 3 Issue: 3
Author(s): Antonio Rossi, Emilio Bria, Paolo Maione, Giovanni Palazzolo, Marzia Falanga and Cesare Gridelli
Affiliation:
Keywords: EGFR, monoclonal antibodies, NSCLC, cetuximab, panitumumab, matuzumab
Abstract: Lung cancer continues to be the leading cause of cancer-related deaths in the western civilization and developing countries. Non-small cell lung cancer (NSCLC) accounts for > 85% of all cases of lung cancer. Since most patients with NSCLC have advanced disease at diagnosis, to date chemotherapy with third-generation platinum-based doublets represents the standard of care. However, a plateau has been reached with the use of cytotoxic chemotherapy in advanced NSCLC. Advances in the knowledge of tumour biology and mechanisms of oncogenesis have granted the singling out of several molecular targets for NSCLC treatment. In particular, the epidermal growth factor receptor (EGFR), a member of the ErbB family and commonly overexpressed in NSCLC, is one of the most studied targets. Overexpression of EGFR has been associated with a poorer prognosis in patients with cancer, therefore its inhibition may lead to the suppression of tumor proliferation improving clinical outcome. Strategies to block EGFR include development of monoclonal antibodies to EGFR, tyrosine kinase inhibitors, ligand-linked toxins, and antisense approaches. This article will focus on cetuximab and other monoclonal antibodies and their applications in the treatment of advanced NSCLC.
Export Options
About this article
Cite this article as:
Rossi Antonio, Bria Emilio, Maione Paolo, Palazzolo Giovanni, Falanga Marzia and Gridelli Cesare, The Role of Cetuximab and Other Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Advanced Non-Small Cell Lung Cancer, Reviews on Recent Clinical Trials 2008; 3 (3) . https://dx.doi.org/10.2174/157488708785700276
DOI https://dx.doi.org/10.2174/157488708785700276 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging
Current Radiopharmaceuticals Production of Lentivectors for Clinical Use
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Ferroptosis Inducers for Prostate Cancer Therapy
Current Medicinal Chemistry Eph as a Target in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Genome-Wide Integrated Analyses of Androgen Receptor Signaling in Prostate Cancer Based on High-Throughput Technology
Current Drug Targets Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells
Anti-Cancer Agents in Medicinal Chemistry Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Leptin, Ciliary Neurotrophic Factor, Leukemia Inhibitory Factor and Interleukin- 6: Class-I Cytokines Involved in the Neuroendocrine Regulation of the Reproductive Function
Current Protein & Peptide Science Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery Mitochondrial Dynamics: An Emerging Paradigm in Ischemia-Reperfusion Injury
Current Pharmaceutical Design The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Regulation and Therapeutic Approaches in Cancer
Current Topics in Medicinal Chemistry Exosomes: A Promising Factor Involved in Cancer Hypoxic Microenvironments
Current Medicinal Chemistry Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Molecular Imaging of Breast Cancer: Role of RGD Peptides
Mini-Reviews in Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Breath Analysis Using SIFT-MS to Assess Metabolic Status in Patients After Gastro-oesophageal Cancer Surgery- a Pilot Study
Current Analytical Chemistry Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Current Drug Targets